STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)
A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308) Read Moreabout STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308)
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303) Read Moreabout ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
Phase: III
Ph2 clinical trial of BNT327 in combo with treatment in breast cancer
A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02) Read Moreabout Ph2 clinical trial of BNT327 in combo with treatment in breast cancer
Phase: II
Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001) Read Moreabout Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04)
Phase: III
Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657) Read Moreabout Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
Phase: III
Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010) Read Moreabout Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer
Phase: II
Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase: III
Ph3 study of standard endocrine therapy with breast cancer
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422) Read Moreabout Ph3 study of standard endocrine therapy with breast cancer
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph3 study of GOG-3104 with endometrial cancer
A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769) Read Moreabout Ph3 study of GOG-3104 with endometrial cancer
Phase: III
STAR Ph3 study to evaluate to treat patients with HNSCC
A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02) Read Moreabout STAR Ph3 study to evaluate to treat patients with HNSCC
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012) Read Moreabout Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
Phase: II
Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001) Read Moreabout Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12)
Phase: III
STAR: PH1/3 Biomarker unresectable stg3 NSCLC
A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II
Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA) Read Moreabout Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA)
Phase: III
STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101) Read Moreabout STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE)
Phase: I/II